Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tacoma, Washington 98418


Purpose:

This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.


Criteria:

Inclusion: - Healthy men and women between 18 and 50 years old. - Women must be of non-child-bearing potential (not able to have children). - Must be of normal body weight.


NCT ID:

NCT00633048


Primary Contact:

Study Director
Medical Monitor
Wyeth


Backup Contact:

N/A


Location Contact:

Tacoma, Washington 98418
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.